Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates

Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of$ 0.32. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.38%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.11 per share when it actually produced a loss of $0.31, delivering a surprise of -181.82%. Over the last four quarters, ...